ESG

With a fresh $11.5M Series A, Clarasight is using AI to unify fragmented travel and expense data, promising massive savings for global enterprises.

A new cell-free therapy, Ultrasome™, shows a 93% response rate in a pilot study, offering a scalable, regenerative solution for millions with knee pain.

Camber's new service model guarantees 98% EV charger uptime for fleets, automatically waiving fees if performance falls short. Is this the new standard?

Terminix's new podcast reframes pest management from a reactive chore to a core business strategy, empowering leaders to mitigate operational and financial risks.

A startup's novel 4D mammography system completes its first human trial, promising to detect cancer's molecular fingerprint and slash false positives.

A new HHS agenda reopens the door for controversial peptides, just as a wave of next-gen obesity drugs threatens to upend the entire market.

A new wearable using ultrasound resonance could finally solve the accuracy and calibration problems plaguing blood pressure monitors for a billion patients.

An $850M deal for an Arizona cobalt plant marks a pivotal US-Japan move to secure supply chains for defense, EVs, and advanced tech from rivals.

With a massive Series A, Coultreon Biopharma is advancing a novel SIK3 inhibitor spun out of Galapagos to rival injectable blockbusters for autoimmune disease.

Strong performance in its Materials Group helped Avery Dennison surpass Q1 earnings, offsetting a slight downturn in its strategic Intelligent Labels division.

BRC Therapeutics gets the FDA green light for BRC-002, a novel cannabinoid drug for CRPS, a severe pain condition with no approved US treatments.

Discover the cutting-edge tech behind the silent, zero-emission garbage truck transforming waste management and helping cities meet climate goals.

At Agrishow 2026, EAVISION's new J150 drone showcases advanced AI and terrain-following tech to tackle Brazil's unique agricultural challenges.

The top organic bread brand launches mini bagels to meet consumer demand for smaller portions, a strategic move backed by its powerful social mission.

As it preps a first-in-human study for a deadly genetic heart disease, Nuevocor brings on gene therapy veteran Dr. Monica Shah to lead the charge.

Ascidian Therapeutics to present first human safety data for its Stargardt disease drug, a new RNA editing technology with broad potential for genetic diseases.

At IFAT 2026, Scania presents a versatile portfolio for cities, blending electrification, biofuels, and top-tier safety to navigate the urban future.

A new trade event in Kuala Lumpur signals China's shift from simple exports to a strategy of two-way investment and digital-physical market dominance.

With gonorrhea becoming increasingly resistant to antibiotics, a new $2.6M grant fuels the development of a promising preventative vaccine platform.

Bhutan announces its first International Travel Mart, a bold move to attract elite partners and showcase the visionary Gelephu Mindfulness City.